Navigation Links
CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering
Date:6/24/2009

VIENNA, Va., June 24 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM), a late stage cancer immunotherapy company, today announced that it has entered into a definitive agreement with one institutional investor to sell 12.5 million units, with each unit consisting of one of the Company's common shares and 0.67 warrants to purchase one share of common stock, for gross proceeds of approximately $5.0 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering. The investor has agreed to purchase the units at a purchase price of $0.40 per unit. The warrants, which represent the right to acquire an aggregate of up to 8.375 million common shares, will be exercisable at any time on or after 181 days from the Closing Date and prior to the 5-year anniversary at an exercise price of $0.50 per share, which was above the closing price of the Company's common shares on the NYSE AMEX Market on June 23, 2009. Chardan Capital Markets, LLC acted as placement agent for the offering.

The transaction is expected to close on or about June 29, 2009, subject to satisfaction of customary closing conditions.

Geert Kersten, Chief Executive Officer of CEL-SCI, said: "We are planning to use this money to achieve a number of major milestones, key among them are the acceleration of our H1N1 swine flu work and the validation of our manufacturing facility for contract manufacturing services and to produce our cancer drug Multikine for the planned Phase III clinical trial."

The securities described above are being offered by CEL-SCI Corporation pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offe
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Takes Delivery of New Manufacturing Facility
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Corporation Announces 2008 Financial Results
9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
10. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
11. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website ... are used solely in scientific experiments, is currently celebrating ... in business, Maxim Peptide, which was created by the ... new and updated website that now features a special ... been updated with fascinating articles about peptide research, including ...
(Date:7/11/2014)... July 11, 2014 BCC Research ( ... DIGITAL POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , ... technology reached nearly $140 billion in 2013. This is ... a five-year compound annual growth rate (CAGR) of 28.6%. ... of interesting and exciting possibilities within the broader PCR ...
(Date:7/11/2014)... July 11, 2014  Researchers have pioneered a ... The new technology, called Virtual Finger, allows scientists ... like neurons and synapses using the flat surface ... makes 3D imaging studies orders of magnitude more ... unprecedented level across many areas of experimental biology. ...
(Date:7/10/2014)... 10, 2014 Product and process ... low abundance and are often “lost in the ... , Join presenters Dr. Rowel Tobias, Senior Scientist, ... Anders, Head of Quality at Nanotherapeutics, Inc., to ... can speed detection and quantitation while achieving the ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2
... 14, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... Results and HighlightsWhen: , Monday, February 28, 2011 at 4:30 ... on the Internet.  Simply log onto our Web site listed ... event, a replay of the webcast will be available for ...
... YORK and SAN DIEGO, Feb. 14, 2011 Polaris Group ... announced the enrollment of the first patient in a Phase ... small cell lung cancer (SCLC).  The trial, sponsored by LICR, ... University Medical Center and will soon commence at St. Bartholomew,s ...
... NEW YORK, Feb. 11, 2011 Even with radical ... the Quick Extender Pro penile extender system ... penis enlargement , says QuickExtenderPro.com, the leading provider ... professionals worldwide.   With the emergence of ...
Cached Biology Technology:Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer 2Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer 3QuickExtenderPro.com Penis Extender Device Engineered for Quick, Safe and Effective Alternative to Penis Enlargement Surgery 2
(Date:7/10/2014)... Pa. , July 2, 2014  Unisys Corporation,s (NYSE: ... , Unisys Nederland N.V., today announced that it has ... deliver, implement and manage a new Basic Provision Biometrics solution ... Unisys won the contract with a solution based ... management software. The term of the contract is up to ...
(Date:7/10/2014)... , July 3, 2014 ... Market by Type (Swipe And Area), Material (Optical Prism, ... Healthcare, Commercial Security and Banking & Finance), and Geography ... published by MarketsandMarkets, the global Fingerprint Sensors Market is ... a high CAGR of 16.8% from 2014 to 2020. ...
(Date:7/10/2014)... July 7, 2014 According to ... "Electronic Access Control Systems Market Global Forecast, Market Share, ... global Electronic Access Control systems market was valued at ... grow at a CAGR of 12.6% from 2014 to ... million in 2019. Browse the full Electronic ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5
... Solenosteira macrospira . He does all the work of raising ... the baby snails are his own. The surprising new finding ... S. macrospira in a small club of reproductive outliers ... cannibalism, and the species has one of the most extreme life ...
... YORK, August 28, 2012 Researchers at Polytechnic Institute ... biosensor capable of identifying the smallest single virus particles ... detection in a point-of-care setting and shrink test result ... Arnold, university professor of applied physics and member of ...
... the aminopyridine class not only has the potential to become ... but might also be able to block transmission of the ... involving the Medicines for Malaria Venture (MMV), based in Switzerland, ... University of Cape Town, South Africa. On the basis of ...
Cached Biology News:Male snails babysit for other dads 2Male snails babysit for other dads 3By detecting smallest virus, researchers open possibilities for early disease detection 2By detecting smallest virus, researchers open possibilities for early disease detection 3African research identifies strong candidate for possible single-dose malaria cure 2African research identifies strong candidate for possible single-dose malaria cure 3
... Antibody, Unconjugated Applications: ... dilution of 1/100. IP: Use at ... at an assay dependent dilution. Predicted ... in other applications. Optimal dilutions/concentrations ...
Kit containing MACS equipment and reagents for immunopurification of proteins....
Membrane Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... Successful biomarker discovery projects require ... samples to distinguish clinically relevant data ... CiphergenExpress Data Manager is now available ... sample tracking and data flood inherent ...
Biology Products: